<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00145</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``Subjects should be provided an explanation about the extent to which they will be responsible for any costs for medical treatment required as a result of research-related injury.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=73 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b. Specific Requirements of Gene Transfer Research  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(1). Reproductive Considerations  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To avoid the possibility that any of the reagents employed in the gene transfer research could cause harm to a fetus/child, subjects should be given information concerning possible risks and the need for contraception by males and females during the active phase of the study. The period of time for the use of contraception should be specified.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ``The inclusion of pregnant or lactating women should be addressed.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(2). Long-Term Follow-Up  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To permit evaluation of long-term safety and efficacy of gene transfer, the  <!-- PJG 0012 frnewline --> prospective subjects should be informed that they are expected to cooperate in  <!-- PJG 0012 frnewline --> long-term follow-up that extends beyond the active phase of the study. The  <!-- PJG 0012 frnewline --> Informed Consent document should include a list of persons who can be  <!-- PJG 0012 frnewline --> contacted in the event that questions arise during the follow-up period. The  <!-- PJG 0012 frnewline --> principal investigator should request that subjects continue to provide a current address and telephone number.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ``The subjects should be informed that any significant findings resulting from the study will be made known in a timely manner to them and/or their parent or guardian including new information about the experimental procedure, the harms and benefits experienced by other individuals involved in the study, and any long-term effects that have been observed.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(3). Request for Autopsy  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To obtain vital information about the safety and efficacy of gene transfer, subjects should be informed that at the time of death, no matter what the cause, permission for an autopsy will be requested of their families. Subjects should be asked to advise their families of the request and of its scientific and medical importance.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(4). Interest of the Media and Others in the Research  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To alert subjects that others may have an interest in the innovative character of the protocol and in the status of the treated subjects, the subjects should be informed of the following: (i) that the institution and investigators will make efforts to provide protection from the media in an effort to protect the participants' privacy, and (ii) that representatives of applicable Federal agencies (e.g., the National Institutes of Health and the Food and Drug Administration), representatives of collaborating institutions, vector suppliers, etc., will have access to the subjects' medical records.''  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> B. Amendment to Appendix M&hyph;VI of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=3 --> NIH Guidelines Regarding Procedures to be Followed for Expedited Review of Single Patient Human Gene Transfer Experiments  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;VI, Procedures to be Followed for Expedited Review of Single Patient Human Gene Transfer Experiments, will read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ``Appendix M&hyph;VI&hyph;D. Regardless of the method of review, the Points to Consider is the standard of review for all gene transfer protocols; therefore, submission of the Points to Consider is required.''  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=3 --> C. Deletion of Appendix L of the NIH Guidelines Regarding Release into the Environment  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            